MX370488B - Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli. - Google Patents

Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli.

Info

Publication number
MX370488B
MX370488B MX2016007316A MX2016007316A MX370488B MX 370488 B MX370488 B MX 370488B MX 2016007316 A MX2016007316 A MX 2016007316A MX 2016007316 A MX2016007316 A MX 2016007316A MX 370488 B MX370488 B MX 370488B
Authority
MX
Mexico
Prior art keywords
prevention
staphylococcus aureus
escherichia coli
aureus infections
glycoprotein vaccines
Prior art date
Application number
MX2016007316A
Other languages
English (en)
Other versions
MX2016007316A (es
Inventor
Wacker Michael
Kowarik Michael
Wetter Michael
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2016007316A publication Critical patent/MX2016007316A/es
Publication of MX370488B publication Critical patent/MX370488B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones inmunogénicas y vacunas para el tratamiento y prevención de infecciones causadas por Staphylococcus aureus. Estas composiciones inmunogénicas y vacunas comprenden combinaciones de polisacáridos capsulares bioconjugados que están N-ligados a una o más proteínas de vehículo.
MX2016007316A 2013-12-04 2014-12-03 Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli. MX370488B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911919P 2013-12-04 2013-12-04
PCT/EP2014/076468 WO2015082571A1 (en) 2013-12-04 2014-12-03 Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli

Publications (2)

Publication Number Publication Date
MX2016007316A MX2016007316A (es) 2016-09-07
MX370488B true MX370488B (es) 2019-12-16

Family

ID=52007023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007316A MX370488B (es) 2013-12-04 2014-12-03 Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli.

Country Status (13)

Country Link
US (1) US10195262B2 (es)
EP (1) EP3076998A1 (es)
JP (1) JP2016540764A (es)
KR (1) KR20160085359A (es)
CN (1) CN106163550A (es)
AU (1) AU2014359277B2 (es)
BR (1) BR112016012599A2 (es)
CA (1) CA2932225C (es)
EA (1) EA201690859A1 (es)
IL (1) IL245742A0 (es)
MX (1) MX370488B (es)
WO (1) WO2015082571A1 (es)
ZA (1) ZA201603539B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
RU2636346C1 (ru) * 2016-07-01 2017-11-22 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ получения рекомбинантного экзопротеина А Pseudomonas aeruginosa
CN109929786B (zh) * 2017-12-15 2022-05-10 中国科学院天津工业生物技术研究所 发酵法生产酪氨酸的大肠杆菌及其构建方法与应用
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
WO2021127653A1 (en) * 2019-12-20 2021-06-24 Washington University Compositions and methods for immunization against staphylococcus aureus
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517439C (en) * 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
EP3281639B1 (en) * 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
EP2654784B1 (en) * 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens

Also Published As

Publication number Publication date
CA2932225C (en) 2023-01-17
IL245742A0 (en) 2016-07-31
JP2016540764A (ja) 2016-12-28
US10195262B2 (en) 2019-02-05
AU2014359277A1 (en) 2016-06-16
EA201690859A1 (ru) 2016-11-30
CA2932225A1 (en) 2015-06-11
US20160303213A1 (en) 2016-10-20
MX2016007316A (es) 2016-09-07
AU2014359277B2 (en) 2017-10-26
BR112016012599A2 (pt) 2017-09-26
KR20160085359A (ko) 2016-07-15
EP3076998A1 (en) 2016-10-12
ZA201603539B (en) 2019-04-24
CN106163550A (zh) 2016-11-23
WO2015082571A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
MX2016007316A (es) Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
EA201591925A1 (ru) Терапевтические композиции и их применение
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12018500358A1 (en) Compounds for use in an antibacterial applications
TN2016000490A1 (en) Naphthyridinedione derivatives.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
BR112016029761A8 (pt) composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado
MX2018002020A (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
IN2014KN02584A (es)
IN2013CH05858A (es)
MY175015A (en) A composition for diabetic wound treatment

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

FG Grant or registration